Status:
UNKNOWN
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Lead Sponsor:
Gangnam Severance Hospital
Collaborating Sponsors:
Severance Hospital
Samsung Medical Center
Conditions:
Breast Cancer
Recurrent Breast Cancer
Eligibility:
FEMALE
20-75 years
Phase:
PHASE2
Brief Summary
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
Detailed Description
Local treatment included surgical resection, stereotactic body radiotherapy, palliative radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a radiation modality. ...
Eligibility Criteria
Inclusion
- ER-positive/HER2-negative in primary tumor
- Oligometastases: ≤ 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)
- Recurrent cancer after completion of primary treatment (RFI≥1year)
- Metastatic lesions are feasible for resection or radiotherapy (Size≤3cm)
Exclusion
- De Novo metastatic cancer at initial diganosis
- Recurrence-free inverval \< 1 year
Key Trial Info
Start Date :
August 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03750396
Start Date
August 1 2018
End Date
July 31 2025
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea, 135720